Key result
This review discusses the predisposing factors and genetic predisposition for drug-induced Torsades de Pointes, highlighting the future potential for pharmacogenomic-guided personalized prescription.
This review highlights the genetic predisposition to drug-induced Torsades de Pointes and the potential for future pharmacogenomic-guided prescribing to prevent this life-threatening adverse event.
Answers are grounded in this paper and cite their sources.
Pharmacogenomic testing for drug-induced TdP risk should not yet change practice; leaves open need for prospective validation.
Drug-induced Torsades de Pointes is a rare, unpredictable, and life-threatening serious adverse event. It can be caused by both cardiac and non-cardiac drugs and has become a major issue in novel drug development and for the regulatory authorities. This review describes the problem, predisposing factors, and the underlying genetic predisposition as it is understood currently. The future potential for pharmacogenomic-guided and personalized prescription to prevent drug-induced Torsades de Pointes is discussed. Database searches utilized reports from www.qtdrugs.org up to January 2012, case reports and articles from www.pubmed.com up to January 2012, and the British National Formulary edition at www.bnf.org.
No takes yet. Share an insight, caveat, or question.
Behr et al. (2012) conducted a review in Drug-induced Torsades de Pointes. Pharmacogenomic prescribing was evaluated. This review discusses the predisposing factors and genetic predisposition for drug-induced Torsades de Pointes, highlighting the future potential for pharmacogenomic-guided personalized prescription.
Synapse has enriched 10 related papers. Consider them for comparative context: